1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Articles (282) 

Why You Should Buy Dendreon's Drop

July 19, 2014 | About:

Biotechnology organization Dendreon's (DNDN) performance haasn't been extra ordinary in 2014. This doesn't come as an amazement since Dendreon's late final quarter results were feeble with the organization posting a net loss of $296.8 million in the last fiscal year, along with the quarterly income declining 12% year over year. Then again, this net loss was superior to the loss of $393.6 million posted in the earlier financial period, implying that Dendreon is making advancement, despite the fact that it didn't meet analyst desires.

Europe ought to help sales

Dendreon is looking to support sales of its cancer drug Provenge going ahead, as it is going to dispatch it in Europe. Dendreon is concentrating on different portions to enhance profitability. The organization is concentrating on enhancing execution of Provenge, and section into Europe will be a decent move in this bearing.

Europe is a conceivably huge business sector for Dendreon and the accessibility of Provenge to urologists and oncologists and their prostate patients in potential markets will improve the organization's sales and profitability. Further, since Provenge is another remedial alternative for cutting edge prostate growth patients, as it deals with an alternate instrument of activity than different treatments, it is required to perform exceptionally well in these business sectors and will most likely help Dendreon's vigorous execution later on.

Dendreon is making Provenge accessible to doctors and patients through Centers of Excellence, utilizing its agreement producing association, Pharmacell, starting with Germany and the United Kingdom. Focuses of Excellence are establishments where a high volume of prostate malignancy patients are dealt with by heading prostate cancer masters.

Henceforth, Dendreon has made the right move by moving into this business sector, and since it is experiencing Centers of Excellence, it ought to have the capacity to draw in a decent number of patients at first. Also, Dendreon is arranging further extension in Europe once its computerization methodology is sanction as this will help the organization diminish its cost of products sold.

Dendreon has additionally rolled out an assemblage of administration improvements lately to enhance execution and target more markets. The arrangements of a boss showcasing and a boss client officer ought to help Dendreon fabricate significant associations with the clients and patients, furthermore help at the improvement of more sound procedures that ought to upgrade its prospects.

Computerization and enhancing records

Proceeding onward, Dendreon is working nearly with the FDA on computerization forms. Robotization will permit the organization to move into new and existing markets all the more rapidly and productively, permitting Provenge to be all the more comprehensively accessible in Europe and different markets over the world. The support of mechanization ought to prompt piece of the overall industry picks up for Dendreon as it will have the capacity to make its drug at a lower cost and at a speedier space.

Likewise, Dendreon saw upgrades in its oncology and urology accounts by 19% and 2%, individually. In the following quarter, the organization is expecting the situating of Provenge as a cutting edge treatment in metastatic maim safe prostate disease to increase force. Finally, Dendreon is additionally making upgrades to its immuno-oncology pipeline.

Market good fortune

Dendreon's results may have been poor, however the organization's methodologies and changes in its immuno-oncology pipeline look encouraging. The invasion into Europe is a decent move while advance in the computerization approbation is required to lower expenses and build creation. In this way, Dendreon is resembling a decent turnaround applicant for what's to come.

Indeed analysts are upbeat about the organization's prospects as they anticipate that income will develop at a rate of 85% in the following five years. This looks achievable since the prostate disease drug business sector is required to develop at a CAGR of 10% till 2022, arriving at a size of $8.6 billion in real markets. With Provenge, Dendreon is decently situated to assault this open door and financial specialists ought to keep on belieing in its prospects.

Rating: 0.0/5 (0 votes)


Please leave your comment:

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Performances of the stocks mentioned by JuhiKulkarni

User Generated Screeners

pbarker46Begin here 3
DBrizan2017sep22 1045p
andrewgu999nick scali style
liuzishudeep value non-div
star1907Rule #1
star1907C3 20% Growth 5 yr
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat